NERV
Price
$1.66
Change
-$0.04 (-2.35%)
Updated
Apr 1, 02:30 PM (EDT)
Capitalization
12.66M
42 days until earnings call
ZLDPF
Price
$75.60
Change
-$0.50 (-0.66%)
Updated
Mar 31 closing price
Capitalization
5.66B
Ad is loading...

NERV vs ZLDPF

Header iconNERV vs ZLDPF Comparison
Open Charts NERV vs ZLDPFBanner chart's image
Minerva Neurosciences
Price$1.66
Change-$0.04 (-2.35%)
Volume$5K
Capitalization12.66M
Zealand Pharma A/S
Price$75.60
Change-$0.50 (-0.66%)
Volume$236
Capitalization5.66B
NERV vs ZLDPF Comparison Chart
Loading...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NERV vs. ZLDPF commentary
Apr 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NERV is a StrongBuy and ZLDPF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 01, 2025
Stock price -- (NERV: $1.70 vs. ZLDPF: $75.60)
Brand notoriety: NERV and ZLDPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NERV: 43% vs. ZLDPF: 29%
Market capitalization -- NERV: $12.66M vs. ZLDPF: $5.66B
NERV [@Biotechnology] is valued at $12.66M. ZLDPF’s [@Biotechnology] market capitalization is $5.66B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NERV’s FA Score shows that 0 FA rating(s) are green whileZLDPF’s FA Score has 1 green FA rating(s).

  • NERV’s FA Score: 0 green, 5 red.
  • ZLDPF’s FA Score: 1 green, 4 red.
According to our system of comparison, NERV is a better buy in the long-term than ZLDPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NERV’s TA Score shows that 4 TA indicator(s) are bullish.

  • NERV’s TA Score: 4 bullish, 4 bearish.

Price Growth

NERV (@Biotechnology) experienced а -8.11% price change this week, while ZLDPF (@Biotechnology) price change was -9.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.00%. For the same industry, the average monthly price growth was -12.26%, and the average quarterly price growth was -11.16%.

Reported Earning Dates

NERV is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-8.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLDPF($5.66B) has a higher market cap than NERV($12.7M). NERV YTD gains are higher at: -23.479 vs. ZLDPF (-26.143). NERV has higher annual earnings (EBITDA): 6.02M vs. ZLDPF (-1.02B). ZLDPF has more cash in the bank: 8.23B vs. NERV (21.4M). NERV has less debt than ZLDPF: NERV (0) vs ZLDPF (392M). ZLDPF has higher revenues than NERV: ZLDPF (62.7M) vs NERV (0).
NERVZLDPFNERV / ZLDPF
Capitalization12.7M5.66B0%
EBITDA6.02M-1.02B-1%
Gain YTD-23.479-26.14390%
P/E Ratio9.53N/A-
Revenue062.7M-
Total Cash21.4M8.23B0%
Total Debt0392M-
FUNDAMENTALS RATINGS
NERV vs ZLDPF: Fundamental Ratings
NERV
ZLDPF
OUTLOOK RATING
1..100
687
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
10053
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
6389
P/E GROWTH RATING
1..100
424
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (57) in the Biotechnology industry is in the same range as ZLDPF (79) in the null industry. This means that NERV’s stock grew similarly to ZLDPF’s over the last 12 months.

ZLDPF's Profit vs Risk Rating (53) in the null industry is somewhat better than the same rating for NERV (100) in the Biotechnology industry. This means that ZLDPF’s stock grew somewhat faster than NERV’s over the last 12 months.

ZLDPF's SMR Rating (95) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that ZLDPF’s stock grew similarly to NERV’s over the last 12 months.

NERV's Price Growth Rating (63) in the Biotechnology industry is in the same range as ZLDPF (89) in the null industry. This means that NERV’s stock grew similarly to ZLDPF’s over the last 12 months.

ZLDPF's P/E Growth Rating (4) in the null industry is somewhat better than the same rating for NERV (42) in the Biotechnology industry. This means that ZLDPF’s stock grew somewhat faster than NERV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NERV
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 19 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SBSW4.580.20
+4.57%
Sibanye-Stillwater
STLD125.081.61
+1.30%
Steel Dynamics
BDN4.460.02
+0.45%
Brandywine Realty Trust
GEOS7.21-0.03
-0.41%
Geospace Technologies Corp
AFMD0.72-0.06
-7.41%
Affimed NV

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with SYRE. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-6.08%
SYRE - NERV
35%
Loosely correlated
-10.06%
CVAC - NERV
35%
Loosely correlated
-7.05%
DNLI - NERV
34%
Loosely correlated
-8.02%
AKRO - NERV
32%
Poorly correlated
-5.24%
ANAB - NERV
30%
Poorly correlated
-1.90%
More

ZLDPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLDPF has been loosely correlated with KRYS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLDPF jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLDPF
1D Price
Change %
ZLDPF100%
-0.66%
KRYS - ZLDPF
46%
Loosely correlated
-1.97%
CLDX - ZLDPF
30%
Poorly correlated
-8.93%
NERV - ZLDPF
22%
Poorly correlated
-6.08%
SNDX - ZLDPF
22%
Poorly correlated
-6.79%
MIST - ZLDPF
22%
Poorly correlated
-9.08%
More